Neurogene Prices Public Offering at $30 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 01 2026
0mins
Neurogene announced the pricing of its previously announced public offering of 3,500,000 shares of its common stock at a public offering price per share of $30.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 666,666 shares of its common stock at a public offering price of $29.999999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.000001 per share and are exercisable immediately. The aggregate gross proceeds to Neurogene from the offering are expected to be approximately $125M before deducting underwriting discounts and commissions and other offering expenses payable by Neurogene, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on July 2, subject to the satisfaction of customary closing conditions. In addition, Neurogene has granted the underwriters an option for a period of 30 days to purchase up to an additional 624,999 shares at the public offering price, less underwriting discounts and commissions. Leerink Partners, Stifel, Guggenheim Securities, LifeSci Capital and William Blair are acting as joint bookrunning managers for the offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NGNE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NGNE
Wall Street analysts forecast NGNE stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 32.560
Low
46.00
Averages
58.00
High
70.00
Current: 32.560
Low
46.00
Averages
58.00
High
70.00
About NGNE
Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Neurogene Prices Public Offering of 3.5M Shares at $30 Each
- Offering Details: Neurogene priced a public offering of 3.5 million common shares at $30.00 each, alongside 666,666 pre-funded warrants for certain investors, which can be exercised immediately at $0.000001 per share, indicating the company's proactive approach to capitalizing on market opportunities.
- Expected Fundraising: The offering is anticipated to raise approximately $125 million in gross proceeds before expenses, which will be utilized to support the company's future research and operations, thereby advancing its gene therapy projects significantly.
- Underwriter's Option: The company granted underwriters a 30-day option to purchase up to an additional 624,999 shares to cover overallotments, a strategy that provides flexibility in financing and enhances market demand for its stock.
- Closing Timeline: The public offering is scheduled to close on July 2, 2026, subject to customary closing conditions, providing investors with a clear timeline for their investment while laying the groundwork for the company's future capital operations.
See More
Neurogene Launches Public Offering to Fund NGN-401 Development
- Public Offering Initiated: Neurogene (NGNE) has commenced a public offering of common stock, allowing certain investors to purchase pre-funded warrants, indicating a positive market response to its financing strategy.
- Underwriter Option: The company expects to grant underwriters a 30-day option to purchase additional shares, enhancing the flexibility of capital raising and potentially supporting future financing efforts.
- Clear Use of Proceeds: The proceeds will fund the clinical development and pre-commercial activities of NGN-401, along with working capital and general corporate purposes, ensuring sustained investment in R&D and operations.
- Increased Market Attention: As Neurogene progresses in gene therapy for Rett syndrome, investor interest in its future potential is rising, which may drive positive stock performance.
See More
Neurogene Reports Positive Long-Term Data for NGN-401 in Rett Syndrome
- Clinical Trial Results: Neurogene's Phase 1/2 study of NGN-401 for Rett syndrome showed that 10 participants achieved a total of 47 developmental milestones, averaging 4.7 milestones per patient, indicating significant efficacy of the therapy.
- Sustained Improvement: All participants improved on the Clinical Global Impression-Improvement (CGI-I) scale, with no loss of milestones reported during the 30-month follow-up, demonstrating the durability of the treatment effects.
- Key Metrics Progress: Participants exhibited progressive improvements across key Rett syndrome measures, with a median time to first clinical improvement of two months post-treatment, highlighting the rapid responsiveness of the therapy.
- Good Safety Profile: As of June 16, 2026, no treatment-related serious adverse events or dose-limiting toxicities were reported in the Embolden registrational trial, further reinforcing confidence in the therapy's safety.
See More
Neurogene Exceeds Dosing Target in NGN-401 Trial
- Dosing Overachievement: Neurogene has successfully dosed 25 participants in the Embolden™ registrational trial of NGN-401, exceeding the initial target of 20 due to strong demand from the Rett syndrome community, highlighting the significant unmet need in this area.
- Good Tolerability: As of June 7, 2026, NGN-401 at the 1E15 vg dose has been generally well-tolerated among 35 participants, with no cases of hemophagocytic lymphohistiocytosis (HLH) reported, indicating satisfactory safety and tolerability for this treatment.
- Data Release Expectations: Neurogene anticipates sharing topline data from the Embolden trial in the second half of 2027, which will serve as the primary analysis for the planned Biologics License Application (BLA), with a required success threshold of a 33% response rate.
- Clinical Development Outlook: NGN-401 is viewed as a potential best-in-class treatment, with Neurogene planning to present updated interim data from the Phase 1/2 trial in mid-2026, further supporting its application potential in treating Rett syndrome.
See More
Neurogene Q1 Earnings Miss Expectations with GAAP EPS of -$1.39
- Earnings Performance: Neurogene reported a Q1 GAAP EPS of -$1.39, missing expectations by $0.09, indicating challenges in profitability that could affect investor confidence moving forward.
- Cash Reserves: As of March 31, 2026, Neurogene's cash, cash equivalents, and short-term investments totaled $243.2 million, which is expected to fund operations through Q1 2028, reflecting a degree of stability in financial management.
- FDA Designation Impact: Despite the disappointing earnings report, Neurogene's stock soared following FDA designation for its Rett syndrome gene therapy, demonstrating market confidence in its potential products and possibly providing momentum for future growth.
- Cautious Investment Advice: Although the stock price surged due to FDA designation, analysts recommend that investors remain cautious given the company's current financial performance and uncertainties ahead, which may impact long-term investment decisions.
See More
Neurogene Advances Gene Therapy with ICV Administration
- ICV Administration Benefits: Neurogene's use of intracerebroventricular (ICV) administration in gene therapy demonstrates broad brain biodistribution, enhancing treatment efficacy, particularly showing multidomain durable improvements in the clinical trial for Rett syndrome.
- Clinical Trial Results: In the Phase 1/2 trial, all eight pediatric participants receiving the 1E15 vg dose exhibited functional improvements, achieving a total of 35 developmental milestones with no plateau observed up to 24 months, indicating the therapy's effectiveness and good tolerability.
- Simplicity of Procedure: The ICV administration procedure takes approximately 10 minutes and is performed tens of thousands of times annually by pediatric and adult neurosurgeons, showcasing its routine clinical application and safety, further enhancing the potential for NGN-401's clinical use.
- Regulatory Recognition: NGN-401 has received multiple designations from the FDA, including Breakthrough Therapy and Regenerative Medicine Advanced Therapy, underscoring its significance and market potential in treating Rett syndrome, with expectations of substantial quality-of-life improvements for patients.
See More
Neurogene Prices Public Offering of 3.5M Shares at $30 Each
- Offering Details: Neurogene priced a public offering of 3.5 million common shares at $30.00 each, alongside 666,666 pre-funded warrants for certain investors, which can be exercised immediately at $0.000001 per share, indicating the company's proactive approach to capitalizing on market opportunities.
- Expected Fundraising: The offering is anticipated to raise approximately $125 million in gross proceeds before expenses, which will be utilized to support the company's future research and operations, thereby advancing its gene therapy projects significantly.
- Underwriter's Option: The company granted underwriters a 30-day option to purchase up to an additional 624,999 shares to cover overallotments, a strategy that provides flexibility in financing and enhances market demand for its stock.
- Closing Timeline: The public offering is scheduled to close on July 2, 2026, subject to customary closing conditions, providing investors with a clear timeline for their investment while laying the groundwork for the company's future capital operations.
See More
Neurogene Launches Public Offering to Fund NGN-401 Development
- Public Offering Initiated: Neurogene (NGNE) has commenced a public offering of common stock, allowing certain investors to purchase pre-funded warrants, indicating a positive market response to its financing strategy.
- Underwriter Option: The company expects to grant underwriters a 30-day option to purchase additional shares, enhancing the flexibility of capital raising and potentially supporting future financing efforts.
- Clear Use of Proceeds: The proceeds will fund the clinical development and pre-commercial activities of NGN-401, along with working capital and general corporate purposes, ensuring sustained investment in R&D and operations.
- Increased Market Attention: As Neurogene progresses in gene therapy for Rett syndrome, investor interest in its future potential is rising, which may drive positive stock performance.
See More
Neurogene Reports Positive Long-Term Data for NGN-401 in Rett Syndrome
- Clinical Trial Results: Neurogene's Phase 1/2 study of NGN-401 for Rett syndrome showed that 10 participants achieved a total of 47 developmental milestones, averaging 4.7 milestones per patient, indicating significant efficacy of the therapy.
- Sustained Improvement: All participants improved on the Clinical Global Impression-Improvement (CGI-I) scale, with no loss of milestones reported during the 30-month follow-up, demonstrating the durability of the treatment effects.
- Key Metrics Progress: Participants exhibited progressive improvements across key Rett syndrome measures, with a median time to first clinical improvement of two months post-treatment, highlighting the rapid responsiveness of the therapy.
- Good Safety Profile: As of June 16, 2026, no treatment-related serious adverse events or dose-limiting toxicities were reported in the Embolden registrational trial, further reinforcing confidence in the therapy's safety.
See More
Neurogene Exceeds Dosing Target in NGN-401 Trial
- Dosing Overachievement: Neurogene has successfully dosed 25 participants in the Embolden™ registrational trial of NGN-401, exceeding the initial target of 20 due to strong demand from the Rett syndrome community, highlighting the significant unmet need in this area.
- Good Tolerability: As of June 7, 2026, NGN-401 at the 1E15 vg dose has been generally well-tolerated among 35 participants, with no cases of hemophagocytic lymphohistiocytosis (HLH) reported, indicating satisfactory safety and tolerability for this treatment.
- Data Release Expectations: Neurogene anticipates sharing topline data from the Embolden trial in the second half of 2027, which will serve as the primary analysis for the planned Biologics License Application (BLA), with a required success threshold of a 33% response rate.
- Clinical Development Outlook: NGN-401 is viewed as a potential best-in-class treatment, with Neurogene planning to present updated interim data from the Phase 1/2 trial in mid-2026, further supporting its application potential in treating Rett syndrome.
See More
Neurogene Q1 Earnings Miss Expectations with GAAP EPS of -$1.39
- Earnings Performance: Neurogene reported a Q1 GAAP EPS of -$1.39, missing expectations by $0.09, indicating challenges in profitability that could affect investor confidence moving forward.
- Cash Reserves: As of March 31, 2026, Neurogene's cash, cash equivalents, and short-term investments totaled $243.2 million, which is expected to fund operations through Q1 2028, reflecting a degree of stability in financial management.
- FDA Designation Impact: Despite the disappointing earnings report, Neurogene's stock soared following FDA designation for its Rett syndrome gene therapy, demonstrating market confidence in its potential products and possibly providing momentum for future growth.
- Cautious Investment Advice: Although the stock price surged due to FDA designation, analysts recommend that investors remain cautious given the company's current financial performance and uncertainties ahead, which may impact long-term investment decisions.
See More
Neurogene Advances Gene Therapy with ICV Administration
- ICV Administration Benefits: Neurogene's use of intracerebroventricular (ICV) administration in gene therapy demonstrates broad brain biodistribution, enhancing treatment efficacy, particularly showing multidomain durable improvements in the clinical trial for Rett syndrome.
- Clinical Trial Results: In the Phase 1/2 trial, all eight pediatric participants receiving the 1E15 vg dose exhibited functional improvements, achieving a total of 35 developmental milestones with no plateau observed up to 24 months, indicating the therapy's effectiveness and good tolerability.
- Simplicity of Procedure: The ICV administration procedure takes approximately 10 minutes and is performed tens of thousands of times annually by pediatric and adult neurosurgeons, showcasing its routine clinical application and safety, further enhancing the potential for NGN-401's clinical use.
- Regulatory Recognition: NGN-401 has received multiple designations from the FDA, including Breakthrough Therapy and Regenerative Medicine Advanced Therapy, underscoring its significance and market potential in treating Rett syndrome, with expectations of substantial quality-of-life improvements for patients.
See More
